Abstract：
The use of generic specialty medications amongst individuals with multiple sclerosis (MS) has expanded due to an increase in the number of available agents. We describe a woman who was denied continued use of brand name teriflunomide (AubagioⓇ), despite being clinically stable for 2.5 years, and switched to generic teriflunomide. She experienced a significant spinal cord exacerbation within a few months of starting treatment. We analyzed 3 generic teriflunomide agents, including the one used for treatment, in addition to AubagioⓇ. The generic teriflunomide used by our patient contained 55.5 % content of the labeled amount, well below U.S. FDA specifications.
摘要：
由于可用药剂数量的增加,在患有多发性硬化症(MS)的个体中通用专业药物的使用已经扩大。我们描述了一个被拒绝继续使用品牌特立氟胺（Aubagio®）的女人，尽管临床稳定了2.5年，改用通用特立氟胺。在开始治疗的几个月内，她经历了严重的脊髓恶化。我们分析了3种特立氟胺药物，包括用于治疗的那个，此外，Aubagio®。我们患者使用的通用特立氟胺含量为标签量的55.5％，远低于美国FDA规范。
